Profilaksis isoniazid merupakan faktor protektif kejadian tuberkulosis pasien HIV/AIDS di klinik VCT RSUP Sanglah Denpasar

I Gusti Putu Hery Sikesa; I Ketut Agus Somia

doi:10.36216/jpd.v5i2.61

Authors

I Gusti Putu Hery Sikesa Program Studi Pendidikan Dokter Spesialis Penyakit Dalam, Fakultas Kedokteran Universitas Udayana / RSUP Sanglah, Denpasar, Bali, Indonesia.
I Ketut Agus Somia Departemen/ KSM Penyakit Dalam, Fakultas Kedokteran Universitas Udayana/ RSUP Sanglah, Denpasar, Bali, Indonesia.

DOI:

https://doi.org/10.36216/jpd.v5i2.61

Keywords:

IPT, Risk of TB, HIV infection

Abstract

Background: Human Immunodeficiency Virus (HIV) infection can increase susceptibility to Mycobacterium tuberculosis (TB) infection. Since Anti Retroviral Therapy (ART) alone is not enough to reduce the risk of TB in HIV patient, a special interventions are needed, namely Isoniazid Preventive Therapy (IPT). In Indonesia, this strategy has not been fully implemented. Therefore, it is necessary to do a research on protective role of IPT against the incidence of TB in HIV/AIDS patients.

Objective: To determine the protective role of IPT in the incidence of TB in patients with HIV/AIDS at the Voluntary and Counseling Test (VCT) Clinic at Sanglah Hospital, Denpasar from 2014 to 2016.

Methods: An observational analytic study with retrospective cohort design was done. All patients who were on HAART therapy and received IPT within the study period were included. The research population were HIV patients who were enrolled in ART follow-up care.

Result: The study found a significant protection effects of IPT on TB incidence [RR: 2.05; 95% IK 1.78-2.37; p=0.02). There was no TB incidence at patients who have received IPT.

Conclusion: Isoniazid Preventive Therapy (IPT) has a significant protection effect on TB incidence.

Keywords: IPT, Risk of TB, HIV infection.

Downloads

Download data is not yet available.

Author Biographies

I Gusti Putu Hery Sikesa, Program Studi Pendidikan Dokter Spesialis Penyakit Dalam, Fakultas Kedokteran Universitas Udayana / RSUP Sanglah, Denpasar, Bali, Indonesia.

Program Studi Pendidikan Dokter Spesialis Penyakit Dalam, Fakultas Kedokteran Universitas Udayana / RSUP Sanglah, Denpasar, Bali, Indonesia.
I Ketut Agus Somia, Departemen/ KSM Penyakit Dalam, Fakultas Kedokteran Universitas Udayana/ RSUP Sanglah, Denpasar, Bali, Indonesia.

Departemen/ KSM Penyakit Dalam, Fakultas Kedokteran Universitas Udayana/ RSUP Sanglah, Denpasar, Bali, Indonesia.

References

Assebe LF, Reda HL, Wubeneh AD,dkk. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.BMC Public Health. 2015;15:346.

Semu M, Fenta TG, Medhin G, dkk. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of AddisAbaba, Ethiopia: a historical cohort study. BMC Infectious Diseases. 2017;17:5.

World Health Organization. Implementing the WHO stop TB strategy: a handbook for national tuberculosis control programmes. Geneva: WHO; 2008.

World Health Organization. Global tuberculosis control: epidemiology,strategy, financing. Diunduh pada 20 Desember 2017.Didapat dari URL: http://www.who.int/tb/ publications/globalreport/2009/en/.

Abossie A, Yohanes T. Assessment of isoniazid preventive therapy in the reduction of tuberculosis among ART patients in Arba Minch Hospital, Ethiopia. Therapeutics and Clinical Risk Management. 2017;13:361–366.

Belay M, Bjune G, Abebe F. Prevalence of tuberculosis, HIV, and TB-HIV co-infection among pulmonary tuberculosis suspects in a predominantly pastoralist area, Northeast Ethiopia. Glob Health Action. 2015;8:10.

Central Statistical Agency dan ORC Macro. Ethiopia Demographic and Health Survey 2005. Ethiopia & Maryland: Central Statistical Agency and ORC Macro; 2006. Diunduh pada 20 Desember 2017. Didapat dari URL: http://www.dhsprogram.com/pubs/pdf/FR179/FR179.

Appunni S, Blignaut R, Lougue S. TB/HIV risk factors identiﬁed from a General Household Survey of South Africa in 2006.Journal of Social Aspects of HIV/AIDS. 2014;11(1):37-41.

Getahun H, Granich R, Sculier D, dkk. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24 (5):57–65.

Geremew D, Endalamaw S, Negash M, dkk. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. BMC Infectious Diseases. 2019; 19:405.

Hawken MP, Meme HK, Elliott LC, dkk. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS. 1997;11:875–82.

Khawcharoenporn T, Apisarnthanarak MW, Sungkanuparph S, dkk. Isoniazid preventive therapy and incidence of pulmonary tuberculosis among HIV-infected patients on antiretroviral therapy: A 4-year study. Int J Tuberc Lung Dis. 2012;16(3):336–41.